Currently out of the existing stock ratings of Matthew Caufield, 110 are a BUY (84.62%), 20 are a HOLD (15.38%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 28.84% that have a potential upside of 25.69% achieved within 66 days.

Matthew Caufield’s has documented 242 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ADVM, Adverum Biotechnologies at 17-Nov-2025.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on HLVX (HILLEVAX).
The best stock recommendation documented was for MLYS (MINERALYS THERAPEUTICS, COMMON STOCK) at 8/13/2025. The price target of $42 was fulfilled within 58 days with a profit of $28.44 (209.73%) receiving and performance score of 36.16.

Average potential price target upside

of $19.11 (151.3%) on MLYS (MINERALYS THERAPEUTICS, COMMON STOCK).
of $12.26 (44.36%) on LENZ (LENZ THERAPEUTICS).
of $11.6 (68.02%) on ISEE (IVERIC BIO).

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals HLVX Hillevax LENZ LENZ Therapeutics MLYS Mineralys Therapeutics, Common Stock FBLG FibroBiologics, Common Stock SRZN Surrozen IMUX Immunic

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score